BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS
March 25 2020 - 9:21AM
BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, today announced
the activation of an expanded service using its Mobile Cardiac
Outpatient Telemetry (MCOT™) to monitor life-threatening QT
prolongation in COVID-19 patients. As a reminder, MCOT is the most
accurate and studied arrhythmia monitoring detection system in the
market. It provides up to 30 days of near real time monitoring
without patients needing to leave their homes. The Company is
currently implementing this COVID-19 monitoring initiative in
several major institutions and physicians have already started
using this service.
Certain medications being used in the treatment of COVID-19
patients, including hydroxychloroquine and azithromycin, can cause
an abnormality in the heart’s electrical system known as QT
prolongation; this serious condition can unfortunately lead to
sudden cardiac arrest or death. As part of its FDA 510(k)
clearance, MCOT has a specific indication for use with patients
requiring measurement, analysis and reporting of QT interval. MCOT
can be used to help physicians monitor and adjust the dosing of
COVID-19 medications, as well as detect any other arrhythmias that
may occur during treatment. As such, patients can benefit from
continuous monitoring using MCOT as a connected solution. This new
program is an “end-to-end” solution including an over-read service
performed by a cardiologist if so desired.
“BioTelemetry’s MCOT provides the unique ability to monitor for
prolonged QT in COVID-19 patients while at the same time providing
an option for hospitals to transition people from inpatient to
outpatient,” said Manish Wadhwa, M.D., F.A.C.C., F.H.R.S., Chief
Medical Officer of BioTelemetry. “As the burden on healthcare
systems worldwide is increasing, remote cardiac monitoring for
these high risk patients provides doctors the necessary information
to adjust treatments, further protecting their patients and freeing
up hospital beds for those most in need.”
Joseph H. Capper, President and Chief Executive Officer of
BioTelemetry, added: “In these stressful times, we are making rapid
adjustments in our business to support the evolving needs of our
customers. The COVID-19 monitoring program we just initiated is an
example of how we are leveraging our technology to support
healthcare providers on the front line of this
battle.
“We are also seamlessly shifting resources to support an
increase in demand for our well-established at-home activation
model, as physicians employ more telehealth visits. Additionally,
we are receiving requests to use MCOT to augment in-patient
telemetry needs as hospital capacity is being over-tasked. We just
implemented this program in two large institutions.
“The message to healthcare providers is simple: We are here to
help in whatever way possible, and thank you for your unbelievable
service.”
About BioTelemetry BioTelemetry, Inc. is
the leading remote medical technology company focused on delivery
of health information to improve quality of life and reduce cost of
care. We provide remote cardiac monitoring, centralized core
laboratory services for clinical trials, remote blood glucose
monitoring and original equipment manufacturing that serves both
healthcare and clinical research customers. More information can be
found at www.gobio.com.
Heather C. GetzInvestor RelationsExecutive Vice
President, Chief Financial
Officer800-908-7103investorrelations@biotelinc.com
Amy M. KnappMedia RelationsVice President,
Corporate Communications813-277-8456amy.knapp@gobio.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024